October 2024

This section reports the findings and recommendations of an important Conference on Guidelines Standardisation (COGS). It also looks into why there is a discrepancy between, for example, CPG and CDR recommendations while discussing the recent case of a new long acting insulin (insulin gargline). It also considers cost-benefit calculations for CPGs, should or should not […]

In this section we shall see what Clinical Practice Guidelines (CPGs) should be and what they are, the recent case of Xigris and a thriller-like manipulation by the concerned company to enter a performance ‘bundle’, CPG effectiveness/cost effectiveness and other considerations, how they serve Industry needs, and what methods can possibly assist them actualise their

In this section, we shall look into issues like code of conduct for industry, voluntary moratorium on spending, why pharma image stinks, the recent goof up about Trasylol (Aprotinin) and what AMCs and medical and research institutes can do to salvage their image vis-à-vis industry collaboration. Go to: Voluntary Moratorium And Code Of Conduct It

Academia-Industry Connect: Value, But With Significant Costs Value As private investment in biomedical research has increased over the last few decades, both industry capital (venture or otherwise) and academia have been quick on the uptake. Huge inflows from the former, and technology transfer offices set up by the latter, have resulted in major academia-industry tie-ups.

Some two decades ago, I was travelling in a bus for a conducted tour of some scenic spot for which organizers of annual conferences of psychiatrists take delegates. Sitting with me was the area manager of the pharmaceutical concern that, if my memory serves me right, had sponsored the tour. As the bus journey took